BIO 2019 Notebook: Merck; RMAT; Out-Licensing Deals

 
• By Joseph Haas and Sue Sutter

News and views from day one of the BIO International Convention: Merck reaffirms commitment to antibiotic space the same day Zerbaxa picks up a new indication; US FDA regenerative medicine advanced therapy designations now outnumber breakthrough designations for cell/gene therapies; BIO survey finds out-licensing cash for emerging firms more than doubled in 2018.

Bio 2019 Notebook for Pink
A total of 36 products within the purview of FDA's tissues/advanced therapies office have received RMAT and 32 got BTD. • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies